Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 15/20 | 0.65 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.64 |
| ▸ | FFAR4 | Q5NUL3 | 5/20 | 0.55 |
| ▸ | CA1 | P00915 | 1/20 | 0.55 |
| ▸ | CA2 | P00918 | 1/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL69746 | 0.88 | FFAR1 (0.81) | FFAR1KEAP1FFAR4CA1CA2 | |
| Hydrochloric Acid SCHEMBL25264643 | 0.85 | FFAR1 (0.77) | FFAR1KEAP1FFAR4CA1CA2 | |
| SCHEMBL1007160 | 0.82 | FFAR1 (0.65) | FFAR1KEAP1FFAR4CA1CA2 | |
| SCHEMBL3533619 | 0.81 | FFAR1 (0.87) | FFAR1KEAP1FFAR4CA1CA2 | |
| SCHEMBL14066660 | 0.81 | FFAR1 (0.87) | FFAR1KEAP1FFAR4CA1CA2 | |
| SCHEMBL11424035 | 0.81 | FFAR1 (0.71) | FFAR1KEAP1FFAR4CA1CA2 | |
| SCHEMBL8437634 | 0.81 | FFAR1 (0.59) | FFAR1KEAP1FFAR4CA1CA2 | |
| SCHEMBL11981977 | 0.79 | KEAP1 (0.61) | FFAR1KEAP1FFAR4 | |
| SCHEMBL7827706 | 0.79 | MAPT (0.69) | FFAR1KEAP1FFAR4CA1CA2 | |
| SCHEMBL12394493 | 0.79 | FFAR1 (1.00) | FFAR1KEAP1FFAR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6596450-B2 | Charge transporting aromatic amines with crosslinkable silane functionalities that are readily prepared and which amines possess an electronic purity in embodiments | XEROX CORPORATION | 2003-07-22 | — | — | US | disclosed |
| US-20030082468-A1 | Charge transport components | XEROX CORPORATION | 2003-05-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030082468-A1 | Charge transport components | SLC43A1, SLC7A5, SLC3A2 | FFAR1 3190/4885KEAP1 2490/4885FFAR4 4396/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.